Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Moro-Sibilot, D., Cozic, N., Pérol, M., Mazières, J., Otto, J., Souquet, P.J., Bahleda, R., Wislez, M., Zalcman, G., Guibert, S.D., Barlési, F., Mennecier, B., Monnet, I., Sabatier, R., Bota, S., Dubos, C., Verriele, V., Haddad, V., Ferretti, G., Cortot, A., De Fraipont, F., Jimenez, M., Hoog-Labouret, N., Vassal, G.
Published in Annals of oncology (01.12.2019)
Published in Annals of oncology (01.12.2019)
Get full text
Journal Article
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Moro-Sibilot, D, Cozic, N, Pérol, M, Mazières, J, Otto, J, Souquet, P J, Bahleda, R, Wislez, M, Zalcman, G, Guibert, S D, Barlési, F, Mennecier, B, Monnet, I, Sabatier, R, Bota, S, Dubos, C, Verriele, V, Haddad, V, Ferretti, G, Cortot, A, De Fraipont, F, Jimenez, M, Hoog-Labouret, N, Vassal, G
Published in Annals of oncology (01.12.2019)
Published in Annals of oncology (01.12.2019)
Get full text
Journal Article